Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · IEX Real-Time Price · USD
455.34
+12.29 (2.77%)
At close: May 31, 2024, 4:00 PM
455.35
+0.01 (0.00%)
After-hours: May 31, 2024, 7:51 PM EDT
Vertex Pharmaceuticals Stock Forecast
Stock Price Forecast
The 20 analysts with 12-month price forecasts for VRTX stock have an average target of 441.4, with a low estimate of 364 and a high estimate of 559. The average target predicts a decrease of -3.06% from the current stock price of 455.34.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for VRTX stock from 25 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
---|---|---|---|---|---|---|
Strong Buy | 7 | 8 | 8 | 8 | 7 | 6 |
Buy | 13 | 13 | 11 | 11 | 12 | 12 |
Hold | 7 | 6 | 7 | 7 | 6 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 1 | 1 | 1 | 1 | 1 |
Total | 27 | 28 | 27 | 27 | 26 | 25 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
RBC Capital | RBC Capital | Hold Maintains $417 → $424 | Hold | Maintains | $417 → $424 | -6.88% | May 7, 2024 |
Piper Sandler | Piper Sandler | Buy Maintains $450 → $456 | Buy | Maintains | $450 → $456 | +0.14% | May 7, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $462 | Strong Buy | Reiterates | $462 | +1.46% | May 7, 2024 |
Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | May 7, 2024 |
Guggenheim | Guggenheim | Strong Buy Maintains $445 → $450 | Strong Buy | Maintains | $445 → $450 | -1.17% | Apr 18, 2024 |
Financial Forecast
Revenue This Year
10.97B
from 9.87B
Increased by 11.10%
Revenue Next Year
11.92B
from 10.97B
Increased by 8.74%
EPS This Year
17.45
from 13.89
Increased by 25.63%
EPS Next Year
18.59
from 17.45
Increased by 6.53%
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 11.5B | 13.8B | 15.2B | 16.6B | 18.7B |
Avg | 11.0B | 11.9B | 13.1B | 14.3B | 15.8B |
Low | 10.3B | 10.8B | 11.5B | 12.1B | 12.9B |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 16.9% | 25.6% | 27.6% | 26.9% | 30.6% |
Avg | 11.1% | 8.7% | 9.6% | 9.6% | 10.1% |
Low | 4.7% | -1.4% | -3.2% | -7.7% | -9.9% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 19.40 | 23.59 | 29.86 | 27.70 | 32.31 |
Avg | 17.45 | 18.59 | 21.16 | 22.08 | 24.60 |
Low | 15.44 | 15.13 | 16.73 | 17.78 | 19.64 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 39.7% | 35.2% | 60.6% | 30.9% | 46.3% |
Avg | 25.6% | 6.5% | 13.8% | 4.3% | 11.4% |
Low | 11.2% | -13.3% | -10.0% | -16.0% | -11.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.